McKinsey January 9, 2025
Careful development of asset strategy across the pharmaceutical R&D pipeline is increasingly important in embracing opportunities for innovation.
Life sciences is on the cusp of a new era of innovation. The convergence of breakthrough technologies, widespread access to data, and deeper insights into complex biological systems is revolutionizing how the industry approaches R&D. For instance, venture capital funding for machine-learning-enabled drug discovery surged more than sevenfold from 2019 to 2022, according to McKinsey analysis. Interest in innovative modalities such as antibody–drug conjugates (ADCs) remains strong, with the top three ADCs expected to bring in $17 billion in global revenue by 2028, and eight of the top ten pharmaceutical companies completing at least one ADC-related acquisition or licensing deal in the...
Today's Sponsors
Today's Sponsor